Turning the Tide on Patient Engagement, Treatment Adherence, and Continuity of Care in Schizophrenia: The Role of Long-Acting Injectables in Optimizing Outcomes
Premiere Date: Thursday, December 30, 2021This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 30, 2022
Note: Credit Is No Longer Available
 | Christoph U. Correll, MD (Moderator) Professor of Psychiatry and Molecular Medicine Zucker School of Medicine at Hofstra/Northwell, New York, USA Professor and Chair, Department of Child and Adolescent Psychiatry Charit? University Medicine, Berlin, Germany |
 | Dawn I. Velligan, PhD Professor, Department of Psychiatry Director, Division of Community Recovery, Research and Training Henry B. Dielmann Chair University of Texas Health Science Center San Antonio, TX |
 | Peter Yellowlees, MBBS, MD Chief Wellness Officer, UC Davis Health Alan Stoudemire Distinguished Endowed Professor of Psychiatry Department of Psychiatry and Behavioral Sciences University of California, Davis Davis, CA |
Schizophrenia is a chronic, debilitating condition that comes with a variety of clinical challenges, including developing patient-centered goals of therapy, navigating social determinants of health (SDOH) that impact access and optimal outcomes, and maintaining long-term, effective therapy. Long-acting injectables (LAIs) are ideal alternatives to oral antipsychotics (OAPs) that are often accompanied by adherence issues. Despite their benefit, LAIs are not routinely presented to patients and caregivers/family as a treatment option, contributing to the underutilization of LAIs in schizophrenia management. To facilitate personalized, optimal, long-term management of schizophrenia, clinicians must identify best practices to incorporate patients and caregivers/family in treatment planning and overcome barriers to the underutilization of LAIs. In addition, to foster long-term management as well as facilitate patient support and augment adherence, strategies to incorporate telemedicine should also be considered.
This CME Outfitters webcast features a collaboration with the American Telemedicine Association (ATA) regarding best practices for incorporating telemedicine in psychiatric management, and will focus on shared decision-making, patient education, and utilizing telemedicine to assist in treatment adherence and supporting patients with schizophrenia.
At the end of this CE activity, participants should be able to:
- Engage in shared decision-making (SDM) strategies with patients with schizophrenia and their caregivers/family to develop patient-centered goals of treatment.
- Educate patients with schizophrenia about the safety and efficacy of LAIs in reducing symptom burden, restoring function, and improving quality of life (QoL).
- Evaluate the impact of continued telemedicine in assisting treatment adherence and supporting patients with schizophrenia.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Correll reports that he receives grants and research support from Janssen Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A, Inc. He reports that he is a consultant for AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc.; Aristo Pharma; Axsome Therapeutics, Inc.; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; IntraCellular Therapies; Janssen Pharmaceuticals, Inc./ Johnson & Johnson; LB Pharmaceuticals.; Lundbeck; Medavante-ProPhase, Inc; MedinCell; Merck & Co., Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceutical Industries Ltd.; and Viatris Inc. He reports that his royalties are up to date.
Dr. Velligan reports that she receives grants from Alkermes and Biogen, Inc. She reports that she is on the speakers bureau for Janssen Pharmaceuticals, Inc. and Otsuka Pharmaceutical, Inc. She reports that she is a consultant for Alkermes, Janssen Pharmaceuticals, Inc.; Lyndra Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; and Teva Pharmaceuticals USA, Inc.
Dr. Yellowlees reports that he is a consultant for HIMS Inc.
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Marlon (Tony) Graham, MD (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WC-046-123021-55
